Featured Research

from universities, journals, and other organizations

Aspirin reduces the risk of cancer recurrence in prostate cancer patients, study suggests

Date:
May 2, 2011
Source:
Fox Chase Cancer Center
Summary:
Some studies have shown that blood-thinning medications, such as aspirin, can reduce biochemical failure the risk of metastasis and even death in localized prostate cancer. These studies, although very telling, have all emphasized the need for more data. Now, with researchers having concluded the largest study on this topic, and there is substantial data suggesting that aspirin improves outcomes in prostate cancer patients who have received radiotherapy.

Some studies have shown that blood-thinning medications, such as aspirin, can reduce biochemical failure--cancer recurrence that is detected by a rising prostate-specific antigen (PSA) level--the risk of metastasis and even death in localized prostate cancer. These studies, although very telling, have all emphasized the need for more data. Now, with researchers at Fox Chase Cancer Center having concluded the largest study on this topic, and there is substantial data suggesting that aspirin improves outcomes in prostate cancer patients who have received radiotherapy.

A team led by Mark Buyyounouski, M.D., M.S., a radiation oncologist at Fox Chase, examined a database of over 2000 prostate cancer patients who underwent radiotherapy at Fox Chase between 1989 and 2006 and found that aspirin use lowers the risk of cancer recurrence. The scientists presented their findings on May 1 at the 93rd Annual Meeting of the American Radium Society.

The team found that the 761 men who took aspirin at or after the time of radiotherapy were less likely to experience biochemical failure--as indicated by the levels of PSA--than were the 1380 men who didn't take the drug.

After 10-years from completion of treatment, 31% of the men who took aspirin developed recurrence compared with 39% of non-aspirin users (p=0.0005). There was also a 2% improvement in 10-year prostate cancer related survival associated with aspirin use with a trend toward statistical significance (p=0.07). "We know that prostate cancer has a long natural history and 15 years or more may be necessary to detect significant difference in survival," Dr. Buyyounouski explains. "Longer follow-up is needed, but these results warrant further study."

The readily available drug could be a promising supplement to radiotherapy in prostate cancer patients, and its beneficial effects may generalize to other types of cancer, Buyyounouski says. Still, he cautions that "it's a little premature to say that men need to start taking aspirin if they have a history of prostate cancer."

The optimal dose, timing, and duration of aspirin therapy, as well as potential side effects are not well understood, Buyyounouski explains. It's not clear how exactly the aspirin is helping and more research is needed to investigate this. "Its possible aspirin therapy is making the radiation more effective or preventing the cancer from spreading."

"Hopefully, these clinical results will provide feedback to laboratory researchers to try to explain the underlying mechanism so that we can better study the clinical effects in targeted populations," Buyyounouski says.

Co-authors on the study include Tianyu Li and Eric M. Horwitz from Fox Chase.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Aspirin reduces the risk of cancer recurrence in prostate cancer patients, study suggests." ScienceDaily. ScienceDaily, 2 May 2011. <www.sciencedaily.com/releases/2011/05/110502092002.htm>.
Fox Chase Cancer Center. (2011, May 2). Aspirin reduces the risk of cancer recurrence in prostate cancer patients, study suggests. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2011/05/110502092002.htm
Fox Chase Cancer Center. "Aspirin reduces the risk of cancer recurrence in prostate cancer patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/05/110502092002.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins